Oritavancin diphosphate (Orbactiv™) is indicated for acute bacterial skin and skin structure infections (ABSSSI). The recommended dosage for oritavancin diphosphate is a 1,200 mg single dose administered by intravenous infusion over three hours. Oritavancin is a lipoglycopeptide antibiotic with three mechanisms of action that result in concentration-dependent bactericidal activity against clinically relevant gram-positive pathogens. Oritavancin has a prolonged terminal half-life and is excreted unchanged in both urine and feces. No dose adjustment is required on the basis of age or renal function or for patients with moderate hepatic impairment.

Criteria - ALL OF the following must be met:
1. An adult patient with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of the following Gram-positive microorganisms: *Staphylococcus aureus* (including methicillin-susceptible [MSSA] and-resistant [MRSA] isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus dysgalanctiae*, *Streptococcus anginosus* group (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*) and *Enterococcus faecalis* (vancomycin-susceptible isolates only); and
2. A patient-specific, clinically significant reason why the member cannot use vancomycin, linezolid (Zyvox®) or other cost-effective therapeutic equivalent medication(s).

A quantity limit of three vials per 30 days will apply.

**Codes:**
J3490
C9444

**References Used:**
Oklahoma Health Care Authority


Development of utilization management criteria may also involve research into other state Medicaid programs, other payer policies, consultation with experts and review by the Medicaid Clinical Advisory Committee (CAC). These sources may not be referenced individually unless they are specifically published and are otherwise applicable to the criteria at issue.
<table>
<thead>
<tr>
<th>Change Date</th>
<th>Changed By</th>
<th>Description of Change</th>
<th>New Version Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/15/16</td>
<td>Medical Director</td>
<td>Added description above Criteria.</td>
<td>1</td>
</tr>
</tbody>
</table>

C. David Smith, MD